Preclinically, glioblastoma and pancreatic cancer preclinical studies suggest CSF-1R inhibition may combine well with checkpoint immunotherapy [50–52], and a study in melanoma suggested a role for myeloid inhibition in ameliorating cognitive adverse effects [52]; clinical trials reported have shown mixed results [45]. The gene discussed is CSF1R; the disease is melanoma.